Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

FDA's MIDAC Votes in Support of Benefit-Risk Profile of Lumisight Optical Imaging Agent for Breast Cancer Detection

March 9th 2024

The FDA's Medical Imaging Drugs Advisory Committee voted 16 to 2 in support of the benefit-risk profile of Lumisight.

Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC

March 9th 2024

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation

March 8th 2024

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.

ADCs Serve as “Exciting and Effective Drug Delivery System” in HR+/HER2– Breast Cancer

March 8th 2024

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.

Racial Disparities Magnified in Cardiac Dose, Toxicity Differences With RT for Breast Cancer

March 8th 2024

Racial and ethnic disparities for mortality are present in breast cancer, especially as it relates to radiation therapy toxicity and cardiac dose.

Dr Litton on Navigating the Sequencing of PARP Inhibitors in Early-Stage TNBC

March 8th 2024

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer

March 8th 2024

Kevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.

Dr Coopey on Institutional and Societal Initiatives to Support Women in Oncology

March 8th 2024

Suzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.

Dr Coopey on Addressing Gender Disparities in Cancer Care

March 8th 2024

Suzanne B. Coopey, MD, FACS, discusses the importance of addressing gender disparities in cancer care.

Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer

March 7th 2024

Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.

Dr Alvarado on Selecting Breast Conservation Surgery vs Mastectomy After Neoadjuvant Therapy

March 7th 2024

Michael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.

Eftilagimod Alpha Plus Chemotherapy Lead-In Proves Safe in HR+/HER2-Low Breast Cancer

March 7th 2024

Eftilagimod alpha in combination with chemotherapy displayed a manageable safety profile in HR+/HER2-low breast cancer.

Standard of Care Regimens for Second-Line Treatment of HER2+ Metastatic Breast Cancer

March 7th 2024

Laura Spring, MD, and Manali Bhave, MD, discuss findings from the DESTINY-Breast03 trial and how these results have led them to adopt T-DM1 as the new standard of care over lapatinib/capecitabine for second-line treatment of HER2-positive metastatic breast cancer after progression on first-line trastuzumab and a taxane.

Key Clinical Trials in the First-Line Treatment of HER2+ Metastatic Breast Cancer

March 7th 2024

Oncologists discuss key learnings from clinical trials investigating the first-line treatment of patients with HER2-positive metastatic breast cancer, and how these findings help inform their clinical practice regarding selection of optimal systemic therapy regimens.

Dr Blackwood on the Significance of Early Breast Cancer Screenings

March 5th 2024

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

Dr Jagsi on the Implications of the IDEA Trial For Patients With Breast Cancer

March 4th 2024

Reshma Jagsi, MD, DPhil, discusses the implications of the IDEA trial for patients with breast cancer.

EMA Validates MAAs for Datopotamab Deruxtecan in NSCLC and HR+ Breast Cancer

March 4th 2024

MAAs for datopotamab deruxtecan in non–small cell lung cancer and hormone receptor–positive, HER2-negative breast cancer have been validated by the EMA.

Dr Jagsi on the Implications of the IDEA Trial for Radiotherapy Omission in Breast Cancer

March 1st 2024

Reshma Jagsi, MD, Dphil, discusses caveats when interpreting long-term results from the IDEA trial of radiotherapy omission in breast cancer.

Dr Meisel on Perceptions of Patient/Provider Communication in Breast Cancer Care

March 1st 2024

Jane L. Meisel, MD, shares information from a study that evaluated patient-reported perceptions of patient-provider communication in breast cancer care.

Current First-Line Systemic Therapy Options for HER2+ Metastatic Breast Cancer

February 29th 2024

Experts discuss considerations around first-line treatment selection for HER2-positive metastatic breast cancer, including when to diverge from the standard-of-care treatment, as well as the role of brain MRIs at diagnosis.